The new facility is the company’s second plasma center in Jacksonville and has now officially opened for business.
The plasma donated at Biotest Plasma Centers is used to manufacture critical care therapies that treat life-threatening disorders in several therapeutic areas, such as the company’s BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid] and Nabi-HB [Hepatitis B Immune Globulin (Human)].
BPC chief executive officer Jordan Siegel said: "We continue to expand our U.S. plasma collection operations to better serve the thousands of patients world-wide who rely on plasma based therapies."
The company intends to add more than 50 jobs to Jacksonville’s local economy and currently has career opportunities available for Licensed Practical Nurses/Registered Nurses, phlebotomists and various other positions.
BPC is a wholly owned subsidiary of Germany-based Biotest, which provides plasma therapies, researches, develops and manufactures biotherapeutic products with a specialization in immunology and hematology.
Currently, BPC is involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products.
The company owns and manages 17 plasmapheresis centers across the US and a manufacturing facility in Boca Raton, Florida.